BLB(SZ:002286)2019-04-29 16:00Financial Performance - The company reported a total revenue of 369,256,000 RMB for the year 2018, with a cash dividend of 0.30 RMB per 10 shares distributed to shareholders[6]. - The company's operating revenue for 2018 was ¥1,730,012,458.43, an increase of 8.60% compared to ¥1,592,996,189.38 in 2017[19]. - The net profit attributable to shareholders for 2018 was ¥42,952,995.03, a decrease of 13.44% from ¥49,621,887.64 in 2017[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥20,099,765.98, down 45.94% from ¥37,179,905.57 in 2017[19]. - The total operating revenue for the year 2018 was CNY 1,730,012,458.43, representing an 8.60% increase from CNY 1,592,996,189.38 in 2017[52]. - The net profit for the company in 2018 was CNY 42.95 million, showing a year-on-year decline of 13.44%[42]. - The basic earnings per share for 2018 was ¥0.12, a decrease of 7.69% compared to ¥0.13 in 2017[19]. - The diluted earnings per share for 2018 was also ¥0.12, reflecting the same decrease of 7.69% from ¥0.13 in 2017[19]. - The total operating costs for 2018 were CNY 1,487,829,469.53, reflecting an increase of 8.20% compared to the previous year[53]. - The total distributable profit for 2018 was ¥288,310,238.88, after deducting the cash dividend of ¥33,233,040 distributed in 2017[122]. Shareholder Information - The company has maintained its shareholder structure, with Beijing Yongyu Investment Management Co., Ltd. as the current controlling shareholder since March 1, 2017[18]. - The total number of shares is 369,256,000, with 328,636,021 shares (89.00%) being unrestricted and 40,619,979 shares (11.00%) being restricted[171]. - The company reported a reduction of 40,619,154 restricted shares, resulting in a total of 825 restricted shares remaining[171]. - The company has not reported any changes in the equity structure or shareholder structure during the reporting period[173]. - The controlling shareholder is Beijing Yongyu Investment Management Co., Ltd., which was established on July 23, 2014, and focuses on external equity investment[177]. Corporate Governance - The board of directors and senior management have confirmed the accuracy and completeness of the financial report, ensuring no misleading statements or omissions[5]. - The company has fulfilled all commitments made by its controlling shareholders and related parties during the reporting period[123]. - The company committed to maintaining an independent governance structure and operational autonomy, ensuring no interference from controlling entities[124]. - The company emphasizes compliance with legal and regulatory requirements in all related party transactions[124]. - The company has a long-term commitment to uphold these principles and ensure transparency in its operations[124]. Business Operations - The company has not undergone any changes in its main business since its listing, maintaining a consistent operational focus[18]. - The company operates in three main business segments: functional ingredients, human nutrition products, and related platform services[28]. - The company’s business strategy includes a focus on functional foods, which are scientifically proven to have health benefits[11]. - The company has established a dedicated investor relations team to facilitate communication with shareholders and stakeholders[16]. - The company aims to solidify its position as a leading functional ingredient provider, focusing on the health industry and expanding into new emerging biotechnologies[104]. Market and Industry Trends - The global health industry is projected to reach a total scale of 8 trillion yuan by 2020 and 16 trillion yuan by 2030, driven by increasing health awareness and spending[95]. - The aging population in China is expected to grow from 222 million in 2015 to 368 million by 2030, significantly increasing the demand for health-related products and services[92]. - The prevalence of chronic diseases such as hypertension and diabetes is rising, with 260 million people suffering from hypertension and over 100 million from diabetes, highlighting the urgent need for health management solutions[96]. - The demand for low glycemic index (GI) foods is rising, driven by the increasing prevalence of diabetes and obesity, creating new opportunities for health product development[98]. - The functional sugar industry is experiencing rapid growth, with the market potential still largely untapped, positioning the company as a leader in this sector with proprietary technology and strong market presence[101]. Research and Development - Research and development (R&D) investment increased by 13.78% to ¥58,523,544.95, which is 3.38% of operating revenue[65]. - The number of R&D personnel increased by 4.32% to 145, while the proportion of R&D personnel to total employees slightly decreased to 13.78%[65]. - The company applied for 4 invention patents and obtained 1 authorized invention patent during the reporting period[43]. - The company obtained one new invention patent during the reporting period, bringing the total to 56 authorized patents[65]. Risk Management - The company has identified potential risks in its future operations, which are detailed in the report for investor awareness[6]. - The company faces market risks associated with new production capacity, which may not meet sales expectations if market conditions change[105]. - The company is exposed to raw material price volatility, particularly for corn and sugar, which could significantly impact profit margins if prices rise[106]. - The company aims to enhance its product development and market expansion efforts to mitigate risks from fluctuations in downstream customer demand[108]. Environmental Compliance - The company has maintained compliance with environmental regulations, with no environmental violations reported in 2018[159]. - The company’s wastewater discharge met the required standards, with a total COD discharge of 155 tons and ammonia nitrogen discharge of 10.5 tons[159]. - The company has a commitment to environmental monitoring, including wastewater and air pollution control measures[165]. - The company has established a quarterly monitoring schedule for various pollutants, including noise and emissions[165]. Employee and Management Information - The total number of employees in the company is 1,052, with 973 in the parent company and 79 in major subsidiaries[197]. - The company has a strong management team with diverse backgrounds, including independent directors like Zhang Xinrong and Su Yu Hai, who bring expertise in medicine and finance respectively[188][189]. - The total pre-tax remuneration for the board of directors and senior management is 339.6 million yuan, with the highest being 111.65 million yuan for the chairman and general manager[196]. - The management team emphasizes long-term growth and sustainability, ensuring that personal compensation aligns with the company's long-term interests[195].